Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study
暂无分享,去创建一个
H. Harputluoglu | U. Demirci | A. Bilici | M. Gumus | G. Basaran | D. Erdem | A. Sumbul | A. Sezer | I. Çiçin | N. Karadurmuş | S. Aksoy | E. Çubukçu | O. F. Olmez | F. Selçukbiricik | B. Çakar | B. Oksuzoglu | Ç. Arslan | Abdallah T M Shbair | M. Şendur | I. Karadag | S. Sezgin Goksu | M. A. Kaplan
[1] A. Schneeweiss,et al. Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis , 2022, Cancers.
[2] C. Palmieri,et al. Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience , 2022, The breast journal.
[3] J. Lee,et al. Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience , 2022, Cancer research and treatment.
[4] M. Somerfield,et al. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] S. Servitja,et al. Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study) , 2020, Breast Cancer Research and Treatment.
[6] T. M. Hughes,et al. Pathological outcomes of HER2‐positive non‐metastatic breast cancer patients treated with neoadjuvant dual anti‐HER2 therapy and taxane: An Australian experience , 2020, Asia-Pacific journal of clinical oncology.
[7] P. De,et al. The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies. , 2020, American journal of cancer research.
[8] Junjie Li,et al. Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial. , 2020, JAMA oncology.
[9] M. Toi,et al. Neoadjuvant treatment for HER2-positive breast cancer. , 2020, Chinese clinical oncology.
[10] F. Cardoso,et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] P. Fasching,et al. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Rezai,et al. Abstract P2-08-01: Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy – Results of a pooled analysis based on the GBG meta-database , 2019, Poster Session Abstracts.
[13] S. Linn,et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. , 2018, The Lancet. Oncology.
[14] M. Lux,et al. Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis , 2018, Breast Cancer Research and Treatment.
[15] Mike Clarke,et al. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials , 2018, The Lancet. Oncology.
[16] S. Swain,et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] C. Hudis,et al. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience. , 2017, The oncologist.
[18] Mei Liu,et al. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Schneeweiss,et al. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] Paolo Morandi,et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. , 2016, The Lancet. Oncology.
[21] Gideon Blumenthal,et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.
[22] J. Baselga,et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. , 2014, The Lancet. Oncology.
[23] C. Shimizu,et al. Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study) , 2014, Breast Cancer Research and Treatment.
[24] A. Schneeweiss,et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] Richard Pazdur,et al. Pathological complete response and accelerated drug approval in early breast cancer. , 2012, The New England journal of medicine.
[26] P. Fasching,et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] J. Baselga,et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort , 2010, The Lancet.
[28] G. Hortobagyi,et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] A. Schneeweiss,et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. , 2018, European journal of cancer.
[30] Giulia Bianchi,et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.